| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2012-09-06 21:02:09 UTC |
|---|
| Update Date | 2023-02-21 17:18:34 UTC |
|---|
| HMDB ID | HMDB0028700 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Alanylvaline |
|---|
| Description | Alanylvaline, also known as AV or L-ala-L-val, belongs to the class of organic compounds known as peptides. Peptides are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another. Alanylvaline has been detected, but not quantified in, a few different foods, such as anatidaes (Anatidae), chickens (Gallus gallus), and domestic pigs (Sus scrofa domestica). This could make alanylvaline a potential biomarker for the consumption of these foods. Alanylvaline is a secondary metabolite. Secondary metabolites are metabolically or physiologically non-essential metabolites that may serve a role as defense or signalling molecules. In some cases they are simply molecules that arise from the incomplete metabolism of other secondary metabolites. Based on a literature review a significant number of articles have been published on Alanylvaline. |
|---|
| Structure | CC(C)[C@H](NC(=O)[C@H](C)N)C(O)=O InChI=1S/C8H16N2O3/c1-4(2)6(8(12)13)10-7(11)5(3)9/h4-6H,9H2,1-3H3,(H,10,11)(H,12,13)/t5-,6-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| AV | ChEBI | | L-Ala-L-val | ChEBI | | N-L-Alanyl-L-valine | ChEBI | | a-V Dipeptide | HMDB | | AV dipeptide | HMDB | | Ala-val | HMDB | | Alanine valine dipeptide | HMDB | | Alanine-valine dipeptide | HMDB | | Alanyl-valine | HMDB | | L-Alanyl-L-valine | HMDB | | N-Alanylvaline | HMDB | | NSC 89603 | HMDB | | Alanylvaline | ChEBI |
|
|---|
| Chemical Formula | C8H16N2O3 |
|---|
| Average Molecular Weight | 188.227 |
|---|
| Monoisotopic Molecular Weight | 188.116092383 |
|---|
| IUPAC Name | (2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanoic acid |
|---|
| Traditional Name | (2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanoic acid |
|---|
| CAS Registry Number | 3303-45-5 |
|---|
| SMILES | CC(C)[C@H](NC(=O)[C@H](C)N)C(O)=O |
|---|
| InChI Identifier | InChI=1S/C8H16N2O3/c1-4(2)6(8(12)13)10-7(11)5(3)9/h4-6H,9H2,1-3H3,(H,10,11)(H,12,13)/t5-,6-/m0/s1 |
|---|
| InChI Key | LIWMQSWFLXEGMA-WDSKDSINSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as peptides. Peptides are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Peptides |
|---|
| Alternative Parents | |
|---|
| Substituents | - Alpha peptide
- N-acyl-alpha-amino acid
- Valine or derivatives
- N-acyl-alpha amino acid or derivatives
- Alpha-amino acid or derivatives
- Branched fatty acid
- Methyl-branched fatty acid
- Fatty acyl
- Fatty acid
- Amino acid or derivatives
- Amino acid
- Carboximidic acid
- Carboximidic acid derivative
- Carboxylic acid
- Monocarboxylic acid or derivatives
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Organic oxide
- Organic oxygen compound
- Primary aliphatic amine
- Amine
- Organic nitrogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Organooxygen compound
- Organopnictogen compound
- Primary amine
- Carbonyl group
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | -2.49 | Extrapolated |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.61 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.8438 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 7.56 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 259.3 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 851.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 260.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 68.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 157.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 46.2 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 275.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 255.7 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 448.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 616.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 173.2 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 815.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 161.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 181.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 406.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 402.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 207.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Alanylvaline,1TMS,isomer #1 | CC(C)[C@H](NC(=O)[C@H](C)N)C(=O)O[Si](C)(C)C | 1608.9 | Semi standard non polar | 33892256 | | Alanylvaline,1TMS,isomer #2 | CC(C)[C@H](NC(=O)[C@H](C)N[Si](C)(C)C)C(=O)O | 1647.9 | Semi standard non polar | 33892256 | | Alanylvaline,1TMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N)[Si](C)(C)C | 1598.0 | Semi standard non polar | 33892256 | | Alanylvaline,2TMS,isomer #1 | CC(C)[C@H](NC(=O)[C@H](C)N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 1703.8 | Semi standard non polar | 33892256 | | Alanylvaline,2TMS,isomer #1 | CC(C)[C@H](NC(=O)[C@H](C)N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 1667.7 | Standard non polar | 33892256 | | Alanylvaline,2TMS,isomer #1 | CC(C)[C@H](NC(=O)[C@H](C)N[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2155.0 | Standard polar | 33892256 | | Alanylvaline,2TMS,isomer #2 | CC(C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@H](C)N)[Si](C)(C)C | 1615.5 | Semi standard non polar | 33892256 | | Alanylvaline,2TMS,isomer #2 | CC(C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@H](C)N)[Si](C)(C)C | 1737.2 | Standard non polar | 33892256 | | Alanylvaline,2TMS,isomer #2 | CC(C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@H](C)N)[Si](C)(C)C | 2348.6 | Standard polar | 33892256 | | Alanylvaline,2TMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N[Si](C)(C)C)[Si](C)(C)C | 1672.2 | Semi standard non polar | 33892256 | | Alanylvaline,2TMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N[Si](C)(C)C)[Si](C)(C)C | 1686.0 | Standard non polar | 33892256 | | Alanylvaline,2TMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N[Si](C)(C)C)[Si](C)(C)C | 2094.2 | Standard polar | 33892256 | | Alanylvaline,2TMS,isomer #4 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)C(=O)O | 1831.9 | Semi standard non polar | 33892256 | | Alanylvaline,2TMS,isomer #4 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)C(=O)O | 1705.2 | Standard non polar | 33892256 | | Alanylvaline,2TMS,isomer #4 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)C(=O)O | 2350.8 | Standard polar | 33892256 | | Alanylvaline,3TMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@H](C)N[Si](C)(C)C)[Si](C)(C)C | 1707.8 | Semi standard non polar | 33892256 | | Alanylvaline,3TMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@H](C)N[Si](C)(C)C)[Si](C)(C)C | 1769.0 | Standard non polar | 33892256 | | Alanylvaline,3TMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@H](C)N[Si](C)(C)C)[Si](C)(C)C | 1861.7 | Standard polar | 33892256 | | Alanylvaline,3TMS,isomer #2 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)C(=O)O[Si](C)(C)C | 1845.5 | Semi standard non polar | 33892256 | | Alanylvaline,3TMS,isomer #2 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)C(=O)O[Si](C)(C)C | 1784.7 | Standard non polar | 33892256 | | Alanylvaline,3TMS,isomer #2 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)C(=O)O[Si](C)(C)C | 2057.1 | Standard polar | 33892256 | | Alanylvaline,3TMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 1811.6 | Semi standard non polar | 33892256 | | Alanylvaline,3TMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 1818.0 | Standard non polar | 33892256 | | Alanylvaline,3TMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 2032.8 | Standard polar | 33892256 | | Alanylvaline,4TMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 1874.1 | Semi standard non polar | 33892256 | | Alanylvaline,4TMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 1897.7 | Standard non polar | 33892256 | | Alanylvaline,4TMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C)N(C(=O)[C@H](C)N([Si](C)(C)C)[Si](C)(C)C)[Si](C)(C)C | 1823.4 | Standard polar | 33892256 | | Alanylvaline,1TBDMS,isomer #1 | CC(C)[C@H](NC(=O)[C@H](C)N)C(=O)O[Si](C)(C)C(C)(C)C | 1846.1 | Semi standard non polar | 33892256 | | Alanylvaline,1TBDMS,isomer #2 | CC(C)[C@H](NC(=O)[C@H](C)N[Si](C)(C)C(C)(C)C)C(=O)O | 1887.7 | Semi standard non polar | 33892256 | | Alanylvaline,1TBDMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N)[Si](C)(C)C(C)(C)C | 1822.2 | Semi standard non polar | 33892256 | | Alanylvaline,2TBDMS,isomer #1 | CC(C)[C@H](NC(=O)[C@H](C)N[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2136.0 | Semi standard non polar | 33892256 | | Alanylvaline,2TBDMS,isomer #1 | CC(C)[C@H](NC(=O)[C@H](C)N[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2072.7 | Standard non polar | 33892256 | | Alanylvaline,2TBDMS,isomer #1 | CC(C)[C@H](NC(=O)[C@H](C)N[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2319.4 | Standard polar | 33892256 | | Alanylvaline,2TBDMS,isomer #2 | CC(C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@H](C)N)[Si](C)(C)C(C)(C)C | 2062.3 | Semi standard non polar | 33892256 | | Alanylvaline,2TBDMS,isomer #2 | CC(C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@H](C)N)[Si](C)(C)C(C)(C)C | 2111.6 | Standard non polar | 33892256 | | Alanylvaline,2TBDMS,isomer #2 | CC(C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@H](C)N)[Si](C)(C)C(C)(C)C | 2465.1 | Standard polar | 33892256 | | Alanylvaline,2TBDMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2139.5 | Semi standard non polar | 33892256 | | Alanylvaline,2TBDMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2070.8 | Standard non polar | 33892256 | | Alanylvaline,2TBDMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2291.3 | Standard polar | 33892256 | | Alanylvaline,2TBDMS,isomer #4 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O | 2273.4 | Semi standard non polar | 33892256 | | Alanylvaline,2TBDMS,isomer #4 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O | 2105.0 | Standard non polar | 33892256 | | Alanylvaline,2TBDMS,isomer #4 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O | 2426.7 | Standard polar | 33892256 | | Alanylvaline,3TBDMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@H](C)N[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2376.4 | Semi standard non polar | 33892256 | | Alanylvaline,3TBDMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@H](C)N[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2331.1 | Standard non polar | 33892256 | | Alanylvaline,3TBDMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@H](C)N[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2279.3 | Standard polar | 33892256 | | Alanylvaline,3TBDMS,isomer #2 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2504.9 | Semi standard non polar | 33892256 | | Alanylvaline,3TBDMS,isomer #2 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2363.0 | Standard non polar | 33892256 | | Alanylvaline,3TBDMS,isomer #2 | CC(C)[C@H](NC(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2360.5 | Standard polar | 33892256 | | Alanylvaline,3TBDMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2494.4 | Semi standard non polar | 33892256 | | Alanylvaline,3TBDMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2393.4 | Standard non polar | 33892256 | | Alanylvaline,3TBDMS,isomer #3 | CC(C)[C@@H](C(=O)O)N(C(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2341.1 | Standard polar | 33892256 | | Alanylvaline,4TBDMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2744.6 | Semi standard non polar | 33892256 | | Alanylvaline,4TBDMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2620.0 | Standard non polar | 33892256 | | Alanylvaline,4TBDMS,isomer #1 | CC(C)[C@@H](C(=O)O[Si](C)(C)C(C)(C)C)N(C(=O)[C@H](C)N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C | 2315.3 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Alanylvaline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Alanylvaline GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Alanylvaline 35V, Positive-QTOF | splash10-0006-9000000000-0c63ed2ed3890d7eb039 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Alanylvaline 35V, Negative-QTOF | splash10-006x-6900000000-6de901fbbf1d369746d9 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 10V, Positive-QTOF | splash10-00du-3900000000-4adc341da7d4e35aba5c | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 20V, Positive-QTOF | splash10-0006-9100000000-afd34d274e9ba0ba26e0 | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 40V, Positive-QTOF | splash10-05fr-9100000000-e3857d9a1c31ce443317 | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 10V, Negative-QTOF | splash10-000i-0900000000-21f4c3992284aeb8b610 | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 20V, Negative-QTOF | splash10-01bi-4900000000-5c1e30d48afb6f09b4c0 | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 40V, Negative-QTOF | splash10-00xs-9200000000-037e70c3f88aefa9d73a | 2019-02-23 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 10V, Positive-QTOF | splash10-01bi-1900000000-64d94996d829e1b927cc | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 20V, Positive-QTOF | splash10-006x-9400000000-daa10dcd217ebcf097a4 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 40V, Positive-QTOF | splash10-0596-9000000000-7cd325362f1b7e130c3a | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 10V, Negative-QTOF | splash10-000i-0900000000-d676b8effb22d51b94b8 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 20V, Negative-QTOF | splash10-014i-4900000000-6e3d7a045cd7f9d54a27 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Alanylvaline 40V, Negative-QTOF | splash10-006x-9000000000-2a6f678d49b0fc0c92da | 2021-10-11 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-25 | Wishart Lab | View Spectrum |
IR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-03 | FELIX lab | View Spectrum | | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
|---|
| Disease References | | Colorectal cancer |
|---|
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
|
|
|---|
| General References | - Cha MH, Kim KS, Suh D, Yoon Y: Effects of genetic polymorphism of uncoupling protein 2 on body fat and calorie restriction-induced changes. Hereditas. 2007 Nov;144(5):222-7. [PubMed:18031357 ]
- Chen L, Morris K, Laybourn A, Elias D, Hicks MR, Rodger A, Serpell L, Adams DJ: Self-assembly mechanism for a naphthalene-dipeptide leading to hydrogelation. Langmuir. 2010 Apr 6;26(7):5232-42. doi: 10.1021/la903694a. [PubMed:19921840 ]
- Nath M, Pokharia S, Eng G, Song X, Kumar A: New triorganotin (IV) derivatives of dipeptides as models for metal-protein interactions: synthesis, structural characterization and biological studies. Spectrochim Acta A Mol Biomol Spectrosc. 2006 Jan;63(1):66-75. Epub 2005 Jun 9. [PubMed:15950528 ]
- Negri L, Lattanzi R, Giannini E, Colucci MA, Mignogna G, Barra D, Grohovaz F, Codazzi F, Kaiser A, Kreil G, Melchiorri P: Biological activities of Bv8 analogues. Br J Pharmacol. 2005 Nov;146(5):625-32. [PubMed:16113687 ]
|
|---|